Nava Zisapel

Portfolio · 4

FEMSelect

Treatment for Pelvic Floor Ligament Fixation

1 round $900K committed Latest: 2019-12

Vectorious Medical Technologies

Miniature Implant for Left Atrial Monitoring

1 round $10.0M committed Latest: 2018-03

SynVaccine

Design and Construction of Viral-based Products

1 round $1.7M committed Latest: 2017-11

Laminate Medical Technologies

Implanted Device for Renal Vascular Procedures in Dialysis Patients

1 round $8.0M committed Latest: 2017-02

Investment activity

1 portfolio exit on record.

Q&A

What is Nava Zisapel's primary investment focus by sector?

Nava Zisapel primarily focuses on the Health Tech & Life Sciences sector, with all four of her portfolio companies and her single recorded exit falling within this area.

Can you name some of Nava Zisapel's notable portfolio companies?

Nava Zisapel's portfolio includes FEMSelect, which develops treatments for Pelvic Floor Ligament Fixation.

Has Nava Zisapel had any notable exits?

Yes, Nava Zisapel had a notable exit with Vectorious Medical Technologies, which was acquired by Edwards Lifesciences for $497M in September 2025.

What stages of funding does Nava Zisapel typically invest in?

Nava Zisapel has invested across various stages, including Seed rounds, B Rounds, and Convertible Debt rounds.

When did Nava Zisapel make her most recent investments?

Nava Zisapel's most recent recorded investment activity was in December 2019.

What kind of business models do Nava Zisapel's portfolio companies typically have?

Nava Zisapel's portfolio companies primarily operate with a B2B business model, such as SynVaccine, which designs and constructs viral-based products.